Walmart, Home Depot adopt health insurer tactic in drug copay battle
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Home Depot (HD) Declares $1.03 Quarterly Dividend; 2.3% Yield
November 15, 2018 4:04 PM ESTHome Depot (NYSE: HD) declared a quarterly dividend of $1.03 per share, or $4.12 annualized.
The dividend will be payable on December 13, 2018, to stockholders of record on November 29, 2018, with an ex-dividend date of November 28, 2018.
The annual yield on the dividend is 2.3... More
CVS Health (CVS) Releases Statement on FDA Decision to Restrict Flavored Tobacco Products
November 15, 2018 11:16 AM ESTCVS Health (NYSE: CVS) today announced its support for the U.S. Food and Drug Administration's plans to restrict access to flavored tobacco and e-cigarette products in the retail setting and impose stricter age-verification requirements for online sales. In addition to eliminating the sale of tobacco products in 2014, CVS Health has never sold e-cigarettes or vaping devices in any of its CVS Pharmacy locations.
"We applaud the FDA's decision to restrict access to flavored tobacco and e-cigarette products, which have been expertly marketed and targeted at teens and young adults and... More
Alector Initiates Phase 1 Trial of AL002 for Treatment of Patients with Alzheimer’s Disease
November 15, 2018 7:08 AM ESTAlector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of a first-in-human Phase 1 trial called the INVOKE study, investigating the companys second product candidate, AL002, for the treatment of patients with Alzheimers disease. AL002 targets a triggering receptor expressed on myeloid cells 2 (TREM2), which was identified using large scale human genomic studies of Alzheimers disease patients. In 2017, Alector entered a global strategic partnership with AbbVie (NYSE: ABBV) that includes the AL002 program.
At Alector, we believe that Alzheimers... More
